Bhramar Mukherjee appointed associate director for population science at University of Michigan Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BHRAMAR MUKHERJEE was appointed associate director for population science research at The University of Michigan Comprehensive Cancer Center, effective Jan. 15, 2016.

Mukherjee is the John D. Kalbfleisch Collegiate professor of biostatistics and a professor of epidemiology at the U-M School of Public Health. She also serves as the associate chair for biostatistics.

In her new role, she will oversee the center’s research on screening, detection and prevention, as well as research on outcomes, disparities and new models of cancer care delivery.

Mukherjee joined the University of Michigan faculty in 2006. She has received the U-M School of Public Health’s Excellence in Teaching Award and was the recipient this year of the University of Michigan’s Faculty Recognition Award. She is the founding director of a cross-disciplinary summer institute at the School of Public Health to train undergraduates at the intersection of big data and human health. She is also an elected fellow of the American Statistical Association.

Her cancer research has focused on how the interaction between genes and the environment impacts cancer risk. She has studied the roles of diet, physical activity and lifestyle factors, and their interplay with the genetic architecture of an individual.

The associate director for population science position was last held by Stephen Gruber, who is now the director of the University of Southern California Norris Comprehensive Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login